A post shared by The CARE Center (@carecenterto) on
Scientists, although long realizing that cannabis affects humans (1800s), only recently began looking into how cannabis does that.
It was discovered (1990) that cannabinoid receptors were located in brain cells. Yet after showing that tetrahydrocannabinol (1964) fit into these CB1 receptors, scientists still didn't know why the brain had receptors for tetrahydrocannabinol (THC).
So, it was not until after the identification of the first endocannabinoid, anandamide (1992), that the existence of the endocannabinoid system (ECS) was revealed.
More recently (2000s), the endocannabinoid system is recognized as an important regulating system. The ECS is the pathway that allows cells within to communicate to different types of cells, and allows parts of a cell to communicate to other cell parts. Its function is to maintain homeostasis despite fluctuations in the internal and external environments.
The ECS consists of cannabinoid receptors, endogenous cannabinoids, and enzymes that either create or destroy endocannabinoids.
The story of Dr. Raphael Mechoulam from his early days, through his immigration to Israel, and his career as the chief investigator into the chemistry and biology of the world's most misunderstood plant. [1:02:15 hr.]
A cannabinoid receptor antagonist is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids. THCV is an antagonist to CB1 receptors.
Good News with Nurse Heather and Canna Kenny, interview Dr. Robert Melamede, Ph.D. in Molecular Biology and Biochemistry, about his busy retirement, commercializing Phoenix Tears, what Dr. Bob has learned about cannabinoid science, how our endocannbinoid system is part of Human evolution, cannabinoid deficiency, and what happens to the world when we get high. [33 min.]
Dr. Bob Melamede, Ph.D. in Molecular Biology and Biochemistry, is interviewed on CannabisRadio and talks about what cancer eats and how cannabis combats it. Also discussed is why doctors are ignorant to cannabis and endocannabinoid system facts. [32:46 min.]
An endocannabinoid enhancer (eCBE) is a type of cannabinoidergic drug that enhances the activity of the endocannabinoid system by increasing extracellular concentrations of endocannabinoids. Examples of different types of eCBEs include:
Dr. Dustin Sulak, expert on medical cannabis, states the goal of the endocannabinoid system (ECS) is to maintain a stable internal environment despite fluctuations in external environment. In addition, the ECS can influence a person's relationship with the external environment with the administration of cannabinoids, especially THC.
The endocannabinoid system (ECS) is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors. The ECS is involved in a variety of physiological processes including:
A wikipedia quiz with 10 multiple choice questions about the endocannabinoid system. Q. 1: "It is thought that hypothalamic neurons tonically produce endocannabinoids that work to tightly regulate ________. a) Starvation, b) Hunger, c ) Malnutrition, or d) Famine."
Leading clinician in the application of medical cannabis, Dr. Dustin Sulak explains that to help our bodies makes endocannabinoids, we need to eat endocannabinoid-enhancing foods containing essential fatty acids, chocolate, herbs, spices, and teas.
A review of public articles dealing with cannabinoid biology which demonstrates a steady growth of indications for the potential therapeutic use of cannabinoid-related medications targeting pain, obesity, and multiple sclerosis.
Due to the drug war and resulting shortage of cannabis research material, not a lot of cannabis-as-medicine research was conducted until the mid-nineties, when a prominent Israeli scientist, Dr. Ralph Mechoulam, discovered that our bodies not only have receptor sites cued just for cannabinoids, but that our bodies actually produce them internally. Author and cannabis consultant Rick Pfrommer predicts it will be another 20 years before cannabis-based medicines will have a prominent place in the worldwide pharmacopeia again.
Cannabinoidergic, or cannabinergic, means, working on the endocannabinoid neurotransmitters. Related proteins and cellular components, that are involved endocannabinoid signaling such as the cannabinoid receptors, as well as exogenous compounds such as phytocannabinoids or other cannabinoids which modulate the activity of endocannabinoid system, can be described as cannabinoidergic.
An animated look at the ascending and descending pain signal pathways in the presence of either endogenous or exogenous cannabinoids. Leanne Chan's Master's Research Project, produced in collaboration with the University of Toronto and funded by the Quebec Pain Research Network. [5:08 min.]